Table 2.
Summary of jakinib trials.
| JAK Inhibitor | Indication under Investigation | Trial |
|---|---|---|
| ruxolitinib | pediatric moderate-severe chronic GVHD | NCT03774082 |
| hemophagocytic lymphohistiocytosis | NCT04551131 | |
| hypereosinophilic syndrome/primary eosinophilic disorders | NCT03801434 | |
| inflammation in HIV patients | NCT02475655 | |
| severe AA 1 |
NCT04518995, NCT04797650 |
|
| tofacitinib | AS | NCT03502616 |
| SLE | NCT02535689 | |
| cutaneous lupus | NCT03288324 | |
| Sjogren’s syndrome | NCT04496960 | |
| inflammatory eye disease | NCT03580343 | |
| COVID-19 | NCT04469114 | |
| baricitinib | SLE |
NCT02708095, NCT03616912, NCT03616964, NCT03843125 |
| COVID-19 |
NCT04401579, NCT04640168, NCT04421027 |
|
| peficitinib | RA |
NCT01649999, NCT01711814, NCT01565655, NCT02308163, NCT02305849 |
| psoriasis | NCT01096862 | |
| UC | NCT01959282 | |
| impaired renal function | NCT02603497 | |
| delgocitinib | chronic hand eczema |
NCT04871711, NCT04872101, NCT04949841 |
| inverse psoriasis | NCT02695940 | |
| AD |
NCT03725722, NCT03826901 |
|
| upadacitinib | PsA |
NCT03104374, NCT03104400, NCT03104374 |
| AS | NCT03178487 | |
| AD 2 |
NCT03569293, NCT03607422, NCT03568318 |
|
| giant cell arteritis | NCT03725202 | |
| Takayasu arteritis | NCT04161898 | |
| filgotinib | CD |
NCT03077412, NCT02914561, NCT02914600 |
| PsA | NCT03101670 | |
| AS | NCT03117270 | |
| abrocitinib | AD |
NCT03349060, NCT03575871, NCT03720470 |
| itacitinib | acute GVHD 3 | NCT03139604 |
| asthma | NCT04129931 | |
| bronchiolitis obliterans syndrome | NCT03978637 | |
| MDS/MPN overlap syndrome | NCT04061421 | |
| SHR0302 | CD | NCT03677648 |
| RA |
NCT02892370, NCT02665910, NCT02423538 |
|
| AS | NCT04481139 | |
| AA | NCT04346316 | |
| AD |
NCT04717310, NCT04162899 |
|
| UC | NCT03675477 | |
| vitiligo | NCT04774809 | |
| deucravacitinib | psoriasis |
NCT03624127, NCT03611751, NCT04167462, NCT03924427, NCT04036435 |
| PsA | NCT03881059 | |
| CD | NCT03599622 | |
| UC | NCT03934216 | |
| SLE | NCT03252587 | |
| brepocitinib | psoriasis 4 | NCT03850483 |
| AD 1 | NCT03903822 | |
| PsA | NCT03963401 | |
| UC | NCT02958865 | |
| CD | NCT03395184 | |
| vitiligo | NCT03715829 | |
| SLE | NCT03845517 | |
| cicatricial alopecia | NCT05076006 | |
| hidradenitis suppurativa | NCT04092452 | |
| AA | NCT02974868 | |
| gusacitinib | AD | NCT03531957 |
| chronic hand eczema | NCT03728504 | |
| cerdulatinib | follicular lymphoma | NCT04021082 |
| T-cell lymphoma | NCT01994382 | |
| vitiligo 4 | NCT04103060 | |
| momelotinib | myelofibrosis | NCT01969838 |
| primary myelofibrosis, post-PV, post-ET myelofibrosis | NCT02101268 | |
| pacritinib | severe thrombocytopenia in myelofibrosis patients | NCT01773187 |
| ritlecitinib | AA | NCT03732807 |
| vitiligo | NCT03715829 | |
| UC | NCT02958865 | |
| CD | NCT03395184 | |
| AA | NCT04006457 | |
| izencitinib | UC | NCT03758443 |
| CD | NCT03635112 | |
| OST-122 | UC | NCT04353791 |
| TD-8236 | asthma |
NCT03652038, NCT04150341 5 |
| nezulcitinib | COVID-19-associated pulmonary disease | NCT04402866 |
1 Deuterated ruxolitinib, CTP-543. 2 As a monotherapy and in combination with topical corticosteroids. 3 Failed to meet primary endpoint. 4 Topical cream formulation. 5 Failed to meet primary endpoint. GVHD: graft-versus-host-disease; AD: atopic dermatitis; HIV: human immunodeficiency virus; AA: alopecia areata; AS: ankylosing spondyloarthritis; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; UC: ulcerative colitis; PsA: psoriatic arthritis; CD: Crohn’s disease; MDS/MPN: myelodysplastic/myeloproliferative; post-PV: post-polycythemia vera; post-ET: post-essential thrombocythemia.